Research
Hormonal
GLP-1 receptor agonists are associated with greater reductions in body weight compared to lifestyle interventions and previous medications.
GLP-1 RAs may be a more effective option for weight loss compared to traditional lifestyle changes.
StrongSupportsmedium confidence
Studies show greater reductions in body weight with these medications compared to lifestyle intervention and previous medications.
Why this rating
Based on comparative studies referenced in the abstract.
Source
Glucagon‐like peptide‐1 receptor agonists discontinuation is higher in individuals with overweight and obesity without type 2 diabetes
Gregory J. Grosicki et al. · Diabetes Obesity and Metabolism · 2025
DOI 10.1111/dom.16151
Meta-analysisCited 7×
Read the paper DOI resolved against Crossref · corpus check 2026-06-10
More from this paper
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →